Pesquisar
Roivant Sciences Ltd
ROIVAdicionar à lista de desejos
38.770USD
-0.220-0.56%
Horário de mercado 09/22, 11:22（ET）
28.02BValor de mercado
PerdaP/L TTM
Sobre o {index_name} Roivant Sciences Ltd Empresa
Roivant Sciences Ltd. is a biopharmaceutical company focused on improving the lives of patients by accelerating the development and commercialization of medicines that matter. The Company’s pipeline includes brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis, non-infectious uveitis and cutaneous sarcoidosis; IMVT-1402 and batoclimab, fully human monoclonal antibodies targeting FcRn in development across several IgG-mediated autoimmune indications; and mosliciguat, an inhaled sGC activator in development for pulmonary hypertension associated with interstitial lung disease. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business.
Roivant Sciences Ltd Perfil
Código da empresaROIV
Nome da EmpresaRoivant Sciences Ltd
Data de listagemDec 03, 2020
CEOVenker (Eric)
Número de funcionários750
Tipo de títulosOrdinary Share
Fim do ano fiscalDec 03
Endereço7Th Floor, 50 Broadway
CidadeLONDON
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited Kingdom
Código postalSW1H 0DB
Telefone4412955950
Sitehttp://roivant.com/
Código da empresaROIV
Data de listagemDec 03, 2020
CEOVenker (Eric)
Executivos da empresa Roivant Sciences Ltd
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Keith S. Manchester, M.D.
Dr. Keith S. Manchester, M.D.
Independent Director
Independent Director
1.73M
-11.43%
Dr. Eric Venker, M.D.
Dr. Eric Venker, M.D.
President and Immunovant Chief Executive Officer
President and Immunovant Chief Executive Officer
1.37M
-1.01%
Dr. Frank M. Torti, M.D.
Dr. Frank M. Torti, M.D.
President and Vant Chairman
President and Vant Chairman
258.79K
-5146.11%
Dr. Mayukh Sukhatme, M.D.
Dr. Mayukh Sukhatme, M.D.
President, Chief Investment Officer, Director
President, Chief Investment Officer, Director
253.33K
--
Mr. Matthew Gline
Mr. Matthew Gline
Chief Executive Officer, Director
Chief Executive Officer, Director
143.83K
+42.81%
Ms. Jennifer Humes
Ms. Jennifer Humes
Chief Accounting Officer
Chief Accounting Officer
109.78K
-3.26%
Mr. Ilan Oren
Mr. Ilan Oren
Independent Chairman of the Board
Independent Chairman of the Board
109.16K
+2.45%
Mr. James C. (Jim) Momtazee
Mr. James C. (Jim) Momtazee
Independent Director
Independent Director
92.38K
-3.14%
Mr. Richard Pulik
Mr. Richard Pulik
Chief Financial Officer
Chief Financial Officer
84.48K
-6.81%
Ms. Melissa B. Epperly
Ms. Melissa B. Epperly
Independent Director
Independent Director
430.00
-479.77%
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Keith S. Manchester, M.D.
Dr. Keith S. Manchester, M.D.
Independent Director
Independent Director
1.73M
-11.43%
Dr. Eric Venker, M.D.
Dr. Eric Venker, M.D.
President and Immunovant Chief Executive Officer
President and Immunovant Chief Executive Officer
1.37M
-1.01%
Dr. Frank M. Torti, M.D.
Dr. Frank M. Torti, M.D.
President and Vant Chairman
President and Vant Chairman
258.79K
-5146.11%
Dr. Mayukh Sukhatme, M.D.
Dr. Mayukh Sukhatme, M.D.
President, Chief Investment Officer, Director
President, Chief Investment Officer, Director
253.33K
--
Mr. Matthew Gline
Mr. Matthew Gline
Chief Executive Officer, Director
Chief Executive Officer, Director
143.83K
+42.81%
Ms. Jennifer Humes
Ms. Jennifer Humes
Chief Accounting Officer
Chief Accounting Officer
109.78K
-3.26%
Perguntas frequentes
Quem são os cinco principais acionistas de Roivant Sciences Ltd?
Os cinco principais acionistas de Roivant Sciences Ltd são: Dr. Keith S. Manchester, M.D.
Quantas instituições possuem ações da Roivant Sciences Ltd (ROIV)?
Em 2026Q1, 781 instituições possuíam ações da Roivant Sciences Ltd, com valor de mercado aproximado de 565.52M, representando 79.01% do total de ações. Em comparação com 2025Q4, a participação institucional aumentou em -23023750.00.